A new report from MLB’s Independent Program Administrator shows that just two players on 40-man rosters tested positive for performance-enhancing substances—including chorionic gonadotrophin and testosterone—out of 11,700 drug tests conducted during the 2025 season.
Atlanta Braves outfielder Jurickson Profar was suspended for 80 games on March 31, 2025, after testing positive for chorionic gonadotrophin (hCG), while Philadelphia Phillies left-hander Jose Alvarado received an 80-game suspension without pay for testing positive for exogenous testosterone.
The report, released Dec. 1 by MLB and the Major League Baseball Players Association, covers the period from the beginning of the 2024-2025 off-season through the conclusion of the 2025 postseason. Independent Program Administrator Thomas M. Martin submitted the findings as part of the Joint Drug Prevention and Treatment Program’s requirement to issue an annual public report.
Of the total tests conducted, 9,400 urine samples and 2,300 dried blood spot samples were collected and analyzed. The blood spot samples were specifically tested for human growth hormone.
The UCLA Laboratory reported two adverse findings that resulted in disciplinary action—one detecting hCG and the other testosterone—both classified as performance-enhancing under MLB’s drug prevention program.
The program granted 57 therapeutic use exemptions during the reporting period. The vast majority—54 exemptions—were for attention deficit hyperactivity disorder. The remaining three exemptions covered hypertension, a sleep disorder, and hormone function issues.
The Joint Drug Prevention and Treatment Program operates under an agreement between the Office of the Commissioner of Baseball and the players’ association.